{"organizations": [], "uuid": "9f93b7a3097b9519c5676039ac4d3ee9c08f813b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-alkermes-submits-nda-to-us-fda-for/brief-alkermes-submits-nda-to-u-s-fda-for-alks-5461-for-adjunctive-treatment-of-major-depressive-disorder-idUSASB0C3AQ", "country": "US", "domain_rank": 408, "title": "BRIEF-Alkermes Submits NDA To U.S. FDA For ALKS 5461 FOR ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-31T21:31:00.000+02:00", "replies_count": 0, "uuid": "9f93b7a3097b9519c5676039ac4d3ee9c08f813b"}, "author": "", "url": "https://www.reuters.com/article/brief-alkermes-submits-nda-to-us-fda-for/brief-alkermes-submits-nda-to-u-s-fda-for-alks-5461-for-adjunctive-treatment-of-major-depressive-disorder-idUSASB0C3AQ", "ord_in_thread": 0, "title": "BRIEF-Alkermes Submits NDA To U.S. FDA For ALKS 5461 FOR ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "nda", "sentiment": "negative"}, {"name": "nda to u.s. fda", "sentiment": "negative"}, {"name": "alkermes plc", "sentiment": "none"}, {"name": "alkermes", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 31, 2018 / 7:34 PM / Updated 24 minutes ago BRIEF-Alkermes Submits NDA To U.S. FDA For ALKS 5461 FOR ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER Reuters Staff 1 Min Read \nJan 31 (Reuters) - Alkermes Plc: \n* ALKERMES SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR ALKS 5461 FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-31T21:31:00.000+02:00", "crawled": "2018-01-31T22:07:51.003+02:00", "highlightTitle": ""}